Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shield Therapeutics ( (GB:STX) ) has provided an update.
Shield Therapeutics has confirmed that its issued share capital now comprises 1,068,418,471 ordinary shares of 1.5p each, all carrying equal voting rights and with no shares held in treasury. This updated total voting rights figure serves as the reference denominator for investors assessing whether changes in their holdings trigger disclosure obligations under UK financial transparency rules, ensuring clarity for shareholders and regulators.
The company continues to position its flagship product ACCRUFeR/FeRACCRU as a differentiated, FDA-approved oral iron therapy addressing a sizeable U.S. and global market for iron deficiency and iron deficiency anemia. By highlighting its expanding commercial footprint and long-dated patent coverage, Shield underlines the strategic importance of ACCRUFeR/FeRACCRU to its growth prospects and to stakeholders tracking its market penetration and regulatory reporting status.
The most recent analyst rating on (GB:STX) stock is a Buy with a £0.10 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.
Spark’s Take on STX Stock
According to Spark, TipRanks’ AI Analyst, STX is a Neutral.
The score is held back primarily by weak financial quality (ongoing losses, negative operating/free cash flow, and negative equity), partially offset by improving revenue/margins and moderately constructive price trend signals. Valuation is also constrained by loss-making status and lack of dividend support.
To see Spark’s full report on STX stock, click here.
More about Shield Therapeutics
Shield Therapeutics is a London-listed commercial-stage specialty pharmaceutical group focused on treating iron deficiency and iron deficiency anemia through its novel oral iron therapy ACCRUFeR/FeRACCRU (ferric maltol). The company commercialises the drug in the U.S. and multiple international markets via partners including Viatris, Norgine, Kye Pharmaceuticals, and regional licensees in Asia-Pacific, with patent protection extending into the mid-2030s.
Average Trading Volume: 1,963,661
Technical Sentiment Signal: Buy
Current Market Cap: £94.02M
Learn more about STX stock on TipRanks’ Stock Analysis page.